Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

pembrolizumab 21lenvatinib 8Paclitaxel 5patritumab deruxtecan 3enfortumab vedotin 2belzutifan 2Tretinoin 2Surgical Procedures, Operative 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Capecitabine 2tremelimumab 1trametinib 1poly ICLC 1epacadostat 1efineptakin alfa 1durvalumab 1dabrafenib 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiation 1Pemetrexed 1Levoleucovorin 1Immunotherapy 1Histamine H2 Antagonists 1Histamine Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Histamine H2 Antagonists × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡